12:00 AM
Jan 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ARRY-520: Phase II data

An open-label Phase II trial in 32 patients with relapsed or refractory MM showed that 1.5 mg/m 2 IV ARRY-520 produced 4 partial responses and 2 minimal responses. In a subgroup of 17 patients with MM refractory to both lenalidomide and bortezomib, ARRY-520 led to 2 partial responses and 1 minimal response. Median time...

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >